Branch duct type intraductal papillary mucinous neoplasm (IPMN) is a mucin-producing cystic neoplasm arising from pancreatic branch ducts. It accounts for approximately 50-60% of all IPMNs and is most commonly located in the uncinate process and pancreatic head. On imaging, it appears as a grape-like cystic lesion with demonstrable communication with the main pancreatic duct. Malignancy risk is lower than main duct IPMN (15-25%), and 'worrisome features' such as size, mural nodules, and wall thickening determine the surveillance strategy.
Age Range
50-80
Peak Age
65
Gender
Equal
Prevalence
Common
Branch duct IPMN is characterized by papillary proliferation of neoplastic cells arising from the epithelium of pancreatic branch ducts with mucin production. Mucin accumulation causes cystic dilatation of branch ducts, forming multilocular (grape-like) or unilocular cystic structures. Each cyst represents a dilated branch duct and these cysts communicate with the main pancreatic duct — this communication is typically demonstrable on MRCP and is diagnostically critical. Gastric epithelial subtype is most common in branch duct IPMNs and carries low malignancy potential. However, intestinal or pancreatobiliary subtypes carry higher dysplasia risk. Increasing cyst size, mural nodule development, wall thickening, and secondary main duct dilatation are considered signs of malignant transformation.
On MRCP or T2-weighted sequences, adjacent multilocular cystic structures cluster in a grape-like configuration — this morphology is characteristic of branch duct IPMN. Each cyst represents a dilated branch duct and communicates with the main pancreatic duct through a central channel. This appearance differs from the microcystic 'honeycomb' pattern of serous cystadenoma and the unilocular/paucilocular pattern of mucinous cystic neoplasm.
MRCP demonstrates communication between the cystic lesion and the main pancreatic duct through a thin channel. This communication is the diagnostic criterion for branch duct IPMN and is the most important finding for differentiation from other pancreatic cystic neoplasms.
Report Sentence
MRCP demonstrates communication between the cystic lesion in the pancreatic [head/body/tail] and the main pancreatic duct, consistent with branch duct type IPMN.
On T2-weighted sequences, a grape-like multilocular hyperintense cystic lesion is visualized. Thin septa separate the individual cysts. Each cyst represents a dilated branch duct and shows bright T2 signal due to mucinous content.
Report Sentence
A T2-hyperintense, thin-septated, grape-like multilocular cystic lesion is observed in the pancreatic [location].
In the portal venous phase, a multilocular cystic lesion with fluid density (0-20 HU) is observed within the pancreatic parenchyma. Thin septa may show mild enhancement. The main pancreatic duct is normal in caliber or mildly dilated.
Report Sentence
A multilocular cystic lesion with fluid density measuring [X] mm is observed in the pancreatic [location], primarily suggesting branch duct type IPMN.
Enhancing mural nodule (>5 mm) in the cyst wall or septum — 'worrisome feature' according to Fukuoka guidelines. Shows prominent enhancement in the arterial phase and may herald high-grade dysplasia or invasive carcinoma.
Report Sentence
An enhancing mural nodule measuring [X] mm is observed in the cyst wall/septum; this finding should be considered a 'worrisome feature' according to Fukuoka guidelines.
On transabdominal US, a multiseptated anechoic/hypoechoic cystic lesion is visualized within the pancreatic parenchyma. Septa appear as thin hyperechoic bands. EUS provides higher resolution assessment of mural nodules, septal details, and duct communication.
Report Sentence
A thin-septated cystic lesion measuring [X] mm is observed in the pancreatic [location], potentially consistent with branch duct IPMN; MRI/MRCP is recommended for further evaluation.
Diffusion restriction in a mural nodule on the cyst wall or septum — indicates high cellularity and increases the risk of malignant transformation. The mucin content itself may demonstrate T2 shine-through effect and must be distinguished from true restriction.
Report Sentence
Diffusion restriction is observed in the mural nodule on the cyst wall, warranting evaluation for malignant transformation.
Criteria
Size <3 cm, no mural nodule, no thickened wall/septa, normal main duct (<5 mm), no rapid growth, no pancreatitis history.
Distinct Features
Low malignancy risk (<5%). Imaging surveillance recommended: <10 mm→every 5 years, 10-20 mm→every 2-3 years, 20-30 mm→annual MRI/MRCP. Surveillance may be discontinued if stable.
Criteria
Size ≥3 cm, enhancing mural nodule <5 mm, thickened/enhancing cyst wall, main duct 5-9 mm, growth rate >5 mm/year in last 2 years, lymph nodes, elevated CA 19-9.
Distinct Features
Intermediate malignancy risk (10-20%). EUS-FNA with fluid analysis (CEA >192 ng/mL suggests mucinous neoplasm, cytology) and mural nodule assessment recommended. Referred to surgery if high-risk stigmata detected.
Criteria
Enhancing mural nodule ≥5 mm, main duct ≥10 mm, obstructive jaundice (in head lesions).
Distinct Features
High malignancy risk (40-60%). Surgical resection recommended. In patients unfit for surgery, close surveillance or EUS-guided treatment options are considered.
Distinguishing Feature
Serous cystadenoma shows microcystic ('honeycomb') pattern with each cyst <2 cm; central fibrous scar and sunburst calcification are characteristic. In branch duct IPMN, cysts are generally larger (macrocystic), duct communication is present, and central scar/calcification is not expected. Serous cystadenoma cyst fluid has low CEA (<5 ng/mL) vs high CEA in IPMN (>192 ng/mL).
Distinguishing Feature
MCN occurs almost exclusively in women (>95%), located in the body-tail, is unilocular/paucilocular cystic with NO communication with the pancreatic duct. Branch duct IPMN occurs in both sexes, is more common in the head/uncinate process, and shows duct communication. MRCP is the gold standard for this distinction.
Distinguishing Feature
Pseudocyst is associated with pancreatitis history, appears as a unilocular homogeneous fluid-density collection with thin smooth enhancing wall and no mural nodules. Branch duct IPMN is multilocular, demonstrates duct communication, does not require pancreatitis history, and may contain mural nodules.
Distinguishing Feature
True pancreatic cyst appears as a unilocular, thin-walled, homogeneous fluid signal simple cyst with no septa, mural nodules, or solid components. Duct communication is usually absent. Branch duct IPMN is distinguished by its multilocular, septated structure with duct communication.
Urgency
surveillanceManagement
surveillanceBiopsy
Not NeededFollow-up
annualMost branch duct IPMNs carry low malignancy risk and are followed with imaging surveillance. Risk stratification is performed according to Fukuoka international consensus guidelines: if no worrisome features, follow-up interval is determined by size (annual MRI/MRCP); if worrisome features present, EUS-FNA is recommended; if high-risk stigmata present, surgical resection is considered. In multifocal branch duct IPMNs, each cyst is evaluated individually. During follow-up, size increase >5 mm/year, new mural nodule development, or main duct dilatation necessitates management change. Patient age and comorbidities are important in surgical decision-making.
Branch duct IPMN has low malignancy risk and can be managed with surveillance if <3cm, no mural nodule, and no main duct dilatation. Per Fukuoka guidelines, worrisome features include: size >3cm, thickened wall, mural nodule. Surgery is recommended in the presence of high-risk stigmata.